Cymbalta (duloxetine) received FDA approval for fibromyalgia

June 18, 2008

Depression drug Cymbalta approved for treating fibromyalgia pain.

Results from two three-month clinical trials involving 874 patients with fibromyalgia have led to a new Food & Drug Administration approval for duloxetine (Cymbalta, Eli Lilly). The serotonin-norepinephrine reuptake inhibitor has been shown to reduce pain in patients with the disorder-51% and 55% of patients taking duloxetine in each study experienced a 30% improvement in the Brief Pain Inventory (BPI) 24-hour average pain scale. In addition, 65% and 66% of patients taking the drug reported feeling better since the beginning of treatment as measured by the Patient Global Impression of Improvement. Duloxetine was previously approved by the FDA for the treatment of diabetic peripheral neuropathic pain, major depression, and generalized anxiety disorder in adults.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.